Back to Media Coverage

FDA GREEN LIGHTS INSIGHTEC'S NEXT-GEN NONINVASIVE ULTRASOUND FIBROID DEVICE EXABLATE

October 8, 2015
icons for web-03.png

Elbit Imaging Ltd. (TASE, NASDAQ: EMITF) ("Elbit" or the "Company") announced today that it was informed by INSIGHTEC Ltd. ("INSIGHTEC"), that the United States Food and Drug Administration (FDA) has approved InSightec's next generation Exablate system to treat symptomatic uterine fibroids and changed the labeling to allow consideration for women who desire to maintain fertility. The updated labeling specifies that ablation of uterine fibroid tissue can now be considered for women with symptomatic uterine fibroids, who desire to retain fertility and spare their uterus.

 

Read more

Media Contacts:

Please fill in the following details and we will get in touch with you. (* Required)

agreement Error

Thank You!

Thank you for contacting us! We will get back to you shortly.

Thank You!

This site is brought to you by INSIGHTEC, © 2018 INSIGHTEC Ltd. All rights reserved.

NGSoft logo